Plasminogen activating factors from DSPA for the treatment of stroke at a dosage of 62.5 to 230 micrograms/kg

Disclosed is the use of the plasminogen activating factor of Desmodus rotundus (DSPA) or a pharmaceutically acceptable salt thereof for the manufacture of an intravenously applicable medicament for the treatment of stroke wherein the dosage is from 62.5 to 230 micrograms/kg.

Saved in:
Bibliographic Details
Main Authors SOHNGEN, WOLFGANG, SCHLEUNING, WOLF-DIETER, SOHNGEN, MARIOLA, MEDCALF, ROBERT
Format Patent
LanguageEnglish
Published 25.06.2010
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Disclosed is the use of the plasminogen activating factor of Desmodus rotundus (DSPA) or a pharmaceutically acceptable salt thereof for the manufacture of an intravenously applicable medicament for the treatment of stroke wherein the dosage is from 62.5 to 230 micrograms/kg.
Bibliography:Application Number: NZ20040543367